This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jones, H. U. Articles by Lappe, D. L. Search for Related Content PubMed PubMed Citation Articles by Jones, H. U. Articles by Lappe, D. L. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Coronary Artery Bypass Surgery Hazardous Substances DB HEPARIN

(Circulation. 2002;106:I-19.)
© 2002 American Heart Association, Inc.

Surgery for Coronary Heart Disease

Preoperative Use of Enoxaparin Compared With Unfractionated Heparin Increases the Incidence of Re-Exploration for Postoperative Bleeding After Open-Heart Surgery in Patients Who Present With an Acute Coronary Syndrome

Clinical Investigation and Reports

Heath U. Jones, BS; Joseph B. Muhlestein, MD; Kent W. Jones, MD; Tami L. Bair, BS; Farangis Lavasani, RN, BSN; Mahtab Sohrevardi, MD; Benjamin D. Horne, MPH; Donald Doty, MD; Donald L. Lappe, MD

From the Cardiovascular Department, LDS Hospital, Salt Lake City, Utah.

Background Enoxaparin has become an attractive therapy for use during acute coronary syndrome (ACS) because of its potential superior efficacy over unfractionated heparin (UFH), its longer activity, and its subcutaneous route of administration. However, because a significant number of patients presenting with ACS may be sent directly to open heart surgery while still on anticoagulation, it is important to understand any potential bleeding risks that may be associated with the use of enoxaparin under these circumstances.

Methods From 1998 to 2001, 1159 consecutive patients presenting with an acute coronary syndrome who received either UFH (n=1008) or enoxaparin (n=151) before proceeding to open heart surgery for urgent therapy during the same hospitalization were included in this study. Incidence of perioperative bleeding as evidenced by the units of blood products (packed red blood cells or platelets) transfused or the need for surgical re-exploration for postoperative bleeding was recorded.

Results Average age was 65±11 and 67±11 years for patients receiving UFH and enoxaparin, respectively (P=0.005). Seventy-five percent of those receiving UFH and 64% of those receiving enoxaparin (P<0.005) were males. After discharge, the incidence of rehospitalization for hemorrhage requiring return to surgery for re-exploration was 7.9% in the enoxaparin group and 3.7% in the UFH group (adjusted hazard ratio=2.6, P=0.03). The use of blood products did not differ between groups (UFH=2.7±6.5 U and enoxaparin=2.3±4.5 U; P=NS).

Conclusion The preoperative use of enoxaparin compared with UFH in patients presenting with an ACS who undergo open-heart surgery during the same hospitalization is associated with a significantly increased incidence of re-exploration for postoperative bleeding. Further study is needed to understand the mechanism of this phenomenon and to develop appropriate guidelines to address this potentially important issue.

Key Words: acute coronary syndrome • enoxaparin • coronary artery bypass graft surgery • re-exploration • hemorrhage